215 results
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
29 May 24
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
8:00am
include:
Safety and tolerability
Overall survival (OS) – median and overall
Tumor response rate (TRR)
Progression-free survival (PFS)
Immunologic … is evaluating overall survival, tumor response rates, and safety and tolerability of VBI-1901 as a monotherapy treatment in rGBM patients
8-K
EX-1.1
VBIVQ
VBI Vaccines Inc
15 May 24
VBI Vaccines Reports First Quarter 2024 Financial Results
4:18pm
without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product … quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
15 May 24
VBI Vaccines Reports First Quarter 2024 Financial Results
4:18pm
visit www.PreHevbrio.com for U.S. Important Safety Information for PreHevbrio [Hepatitis B Vaccine (Recombinant)], or please see U.S. Full Prescribing … is approved for use in adults 18 years of age and older.
U.S. Important Safety Information (ISI)
Do not administer PreHevbrio to individuals with a history
424B5
VBIVQ
VBI Vaccines Inc
15 May 24
Prospectus supplement for primary offering
4:16pm
and Healthcare products Regulatory Agency, Health Canada, or any other health authority and no conclusion can or should be drawn regarding the safety or efficacy
8-K
EX-99.1
s5li7am8
16 Apr 24
VBI Vaccines Reports Full Year 2023 Financial Results
8:00am
8-K
EX-10.1
o91 tz9dsesebd3pt
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
424B5
apgeqea
11 Apr 24
Prospectus supplement for primary offering
9:06am
8-K
EX-99.1
fv1xmdeebfkdxyo4
3 Apr 24
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
8:00am
8-K
EX-99.1
axi5o0z
20 Nov 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
frprxz
14 Nov 23
VBI Vaccines Reports Third Quarter 2023 Financial Results
4:07pm
8-K
EX-99.1
brzc738gbyhfbp4fboyb
27 Sep 23
Regulation FD Disclosure
7:30am
8-K
EX-99.1
3i69a
7 Sep 23
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
8:00am
8-K
EX-99.1
i82gb
6 Sep 23
Regulation FD Disclosure
9:12am